IPO on April 29e, 2021 at 10:00 a.m.
BBS-Bioactive Bone Substitutes Plc corrects its stock market press release published on April 28 at 6:00 p.m. regarding the decisions of the Annual General Meeting. In the Finnish version of the press release, it was incorrectly stated that Tomi Numminen had been elected to the board of directors.
The board of directors consists of Jarmo Halonen, Pekka Jalovaara, Seppo Nevalainen and Kirk Andriano.
The corrected version can be found below in its entirety.
The BBS-Bioactive Bone Substitutes Plc Annual General Meeting (AGM) was held today, Wednesday April 28, 2021 from 2:00 p.m. in Oulu. The general assembly confirmed the financial statements for fiscal year 2020, relieved the board of directors and the general managers of their responsibilities. The general meeting decided that the company would not pay dividends for the financial year 2020.
The advice of redirectors and the auditor
The AGM decided that the number of board members would be four (4). Until the end of the next AGM, were elected Jarmo Halonen, Pekka Jalovaara, Seppo Nevalainen and Kirk Andriano. The general assembly decided that the chairman of the board receives 1300 EUR per meeting and 900 EUR per meeting for the other members. No compensation will be paid for email meetings.
The audit firm Ernst & Young Oy has been re-elected as the Company’s Auditor and KHT Jari Karppinen will act as the Company’s Principal Auditor. The auditor receives a fee based on a reasonable invoice approved by the company.
The general meeting decided to authorize the board to decide on the issue of a share issue which does not exclude the right of the board to decide on a managed share issue. The issue of shares may be exercised to increase the share capital by issuing an issue of shares or convertible bonds in one or more tranches according to the following rules: The Board is authorized to decide to increase the share capital by issuing an issue of shares, issuing a convertible bond, or issuing stock options in one or more tranches. In the new issue or alternatively, convertible loans or stock options may give the right to subscribe for a maximum of 3,000,000 (three million) new shares. The company currently holds 6,571,525 shares. It was decided to terminate the old authorizations.
The authorization includes the right to derogate from the preferential subscription right of shareholders to the subscription of new shares, convertible loans or subscription warrants and to decide on subscription prices, subscription rights and subscription conditions. The subscription price of the shares is recorded in the invested free share fund. The authorization can be used in derogation from the preferential subscription right of the shareholder, provided that there is a significant financial reason for the company, such as the extension of the shareholding of the company or another essential commercial interest. or an arrangement to preserve financial liquidity. By virtue of the authorization, the shares may be offered in derogation from the preferential subscription rights of the shareholder to the related party, but not for the benefit of related parties. The Board is empowered to decide that the shares may be subscribed against payment of the asset, using the right of set-off or otherwise under specific conditions. The available options are used at the discretion of the board.
The authorization is valid until the next AGM but until June 30, 2022.
The minutes of the general meeting are available on the Company’s website www.bbs-artebone.fi no later than May 12, 2021.
For more information:
Ilkka Kangasniemi, CEO,
puh. +35840 7080307, e-mail: [email protected]
Liisa Hukka, Chief Financial Officer,
puh. +35840 0611038, e-mail: [email protected]
Nordic AB certified counselor, p. +46 70 551 67 29, [email protected]
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
BBS-Bioactive Bone Substitutes Plc is the health technology company in business since 2003. Previously, there were seven years of product development at the University of Oulu. We have developed a new product for the healing of difficult bone fractures and for solving bone healing problems. Our mission is to provide new generation drugs for orthopedic surgery. Research and development in medicine takes persistence and courage to develop new things. We have over 20 years of expertise in this field. Our operations are characterized by cutting-edge expertise, capacity for innovation and dedicated and committed employees. The ARTEBONE ® product is ready and the CE marking application process is launched. BBS is the company headquartered in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information: www.bbs-artebone.fi